News & Updates

The mRNA-1237 vaccine against the coronavirus disease 2019 (COVID-19) retains good immunogenicity in patients with mild antibody deficiencies and phagocyte defects, reports a recent study.

Prolonged corrected QT interval (QTc), as determined via electrocardiogram (ECG), may indicate an elevated risk of myocardial injury and death in patients hospitalized for COVID-19, according to a prospective study from Israel presented at EHRA 2022.

Patients who have had to delay their intravenous thrombolysis (IVT) procedures due to the COVID-19 pandemic suffer from worse short-term clinical outcomes such as higher rates of mortality and hospice care, reports a study presented at the Annual Meeting of the American Academy of Neurology (AAN 2022). These patients are also less likely to be discharged to their homes or to rehabilitation facilities.

A recent Mendelian randomization study has found sparse evidence supporting the association of circulating vitamin C levels with the coronavirus disease 2019 (COVID-19) or pneumonia.

An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.

Among patients who successfully recover from the coronavirus disease 2019 (COVID-19), nearly half continue to experience persistent symptoms a month after recovery, reports a recent Japan study.

Treatment with remdesivir in patients hospitalized for COVID-19 does not appear to confer increased risks of acute kidney and liver injury, with a recent study showing that these risks are already elevated even before exposure to treatment and there is no further increase following remdesivir initiation.